These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26114180)

  • 1. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results.
    Arasaradnam RP; McFarlane M; Daulton E; Westenbrink E; O'Connell N; Wurie S; Nwokolo CU; Bardhan KD; Savage RS; Covington JA
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):197-201. PubMed ID: 26114180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
    J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.
    Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY
    World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD).
    Arasaradnam RP; McFarlane M; Daulton E; Skinner J; O'Connell N; Wurie S; Chambers S; Nwokolo C; Bardhan K; Savage R; Covington J
    Dig Liver Dis; 2016 Feb; 48(2):148-53. PubMed ID: 26682719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis--a pilot study.
    Arasaradnam RP; Westenbrink E; McFarlane MJ; Harbord R; Chambers S; O'Connell N; Bailey C; Nwokolo CU; Bardhan KD; Savage R; Covington JA
    PLoS One; 2014; 9(10):e107312. PubMed ID: 25330367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Invasive Diagnosis of Diabetes by Volatile Organic Compounds in Urine Using FAIMS and Fox4000 Electronic Nose.
    Esfahani S; Wicaksono A; Mozdiak E; Arasaradnam RP; Covington JA
    Biosensors (Basel); 2018 Dec; 8(4):. PubMed ID: 30513787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.
    Abrigo JM; Shen J; Wong VW; Yeung DK; Wong GL; Chim AM; Chan AW; Choi PC; Chan FK; Chan HL; Chu WC
    J Hepatol; 2014 Apr; 60(4):809-15. PubMed ID: 24291241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease.
    Sinha R; Lockman KA; Homer NZM; Bower E; Brinkman P; Knobel HH; Fallowfield JA; Jaap AJ; Hayes PC; Plevris JN
    JHEP Rep; 2020 Oct; 2(5):100137. PubMed ID: 32775974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved machine learning pipeline for urinary volatiles disease detection: Diagnosing diabetes.
    Martinez-Vernon AS; Covington JA; Arasaradnam RP; Esfahani S; O'Connell N; Kyrou I; Savage RS
    PLoS One; 2018; 13(9):e0204425. PubMed ID: 30261000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
    Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
    Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children.
    Alkhouri N; Cikach F; Eng K; Moses J; Patel N; Yan C; Hanouneh I; Grove D; Lopez R; Dweik R
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):82-7. PubMed ID: 24284369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of ¹³C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease.
    Fierbinteanu-Braticevici C; Plesca DA; Tribus L; Panaitescu E; Braticevici B
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):149-56. PubMed ID: 23799213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence.
    Cozzolino R; De Giulio B; Martignetti A; Forte G; Dallio M; Romeo M; Scognamiglio F; Ventriglia L; Stocchero M; Federico A
    Metabolomics; 2022 Nov; 18(12):98. PubMed ID: 36441279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath.
    Verdam FJ; Dallinga JW; Driessen A; de Jonge C; Moonen EJ; van Berkel JB; Luijk J; Bouvy ND; Buurman WA; Rensen SS; Greve JW; van Schooten FJ
    J Hepatol; 2013 Mar; 58(3):543-8. PubMed ID: 23142062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
    PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis.
    Yamasaki Y; Nouso K; Miyahara K; Wada N; Dohi C; Morimoto Y; Kinugasa H; Takeuchi Y; Yasunaka T; Kuwaki K; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Iwasaki Y; Amano M; Nishimura S; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):528-34. PubMed ID: 25168691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Liu CH; Ampuero J; Gil-Gómez A; Montero-Vallejo R; Rojas Á; Muñoz-Hernández R; Gallego-Durán R; Romero-Gómez M
    J Hepatol; 2018 Dec; 69(6):1335-1348. PubMed ID: 30142428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.